Browse

Phase III, multicenter, randomized, open-label, parallel-group, non-inferiority, phase III clinical trial comparing CSZ (Lokelma) vs. iSRAA discontinuation/reduction and/or ARM (standard treatment).

Phase 3 • Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia

Last updated Sep 10, 2026 15:00 UTC

Identification of acute intermittent porphyria modifying genes

This study proposes to identify the predisposing/protective modifying genes that underlie the acute attacks in symptomatic patients with Acute Intermittent Porphyria (AIP), an autosomal dominant inborn error of heme biosynthesis.

Sponsor: Icahn School of Medicine at Mount Sinai

Last updated Sep 10, 2026 15:00 UTC

A phase 1 Open-Label, Single-Dose, Parallel-Group study of the pharmacokinetics and safety of VIR-2218 and VIR-3434 monotherapy and combination therapy in adult participants with hepatic impairment

In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be administered to assess the pharmacokinetic (PK) exposure, safety, and tolerability of VIR-2218 and VIR-3434 in participants with cirrhos…

Phase 1 • Sponsor: Vir Biotechnology, Inc.

Last updated Sep 10, 2026 15:00 UTC

Clinical and biological responses to repeated administration of low-dose Interleukin-2 in patients with type 1 diabetes and a residual insulin secretion

Type 1 diabetes (T1D) is caused by the destruction of insulin-producing cells by effector T cells (Teffs), due to a deficiency of regulatory T cells (Tregs). Ciclosporin effectively blocks the Teffs and controls diabetes, but cannot be considered as a long-term treatment. Low-do…

Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris

Last updated Sep 10, 2026 15:00 UTC

A masked, randomized controlled trial evaluating locally-applied gentamicin versus saline in open tibia fractures

Local application of antibiotics directly to the traumatic wound is a promising treatment for the prevention of infection after open tibia fractures, which are a significant source of disease burden globally, particularly in low-income countries. This study aims to measure the ef…

Phase 4 • Sponsor: University of California, San Francisco

Last updated Sep 10, 2026 15:00 UTC

Real-World implementation and effectiveness of tuberculosis preventive treatment in school health services in china

The goal of this study is to learn whether taking short-course preventive treatment in high school and college freshmen with strong positive tuberculosis (TB) skin tests can safely and effectively protect them from developing active TB over a 3-to-4-years period. Main question: …

Phase 4 • Sponsor: Affiliated Hospital of Nantong University

Last updated Sep 10, 2026 15:00 UTC

POS-VAP: perpetual observational study - ventilator associated pneumonia

Ventilator-Associated Pneumonia (VAP) is a bacterial respiratory infection that patients in the Intensive Care Unit (ICU) often get when they cannot breathe for themselves and require mechanical ventilation. It is linked to higher chances of death, a longer stay in the hospital, …

Sponsor: European Clinical Research Alliance for Infectious Diseases (ECRAID)

Last updated Sep 10, 2026 15:00 UTC

A phase i study to evaluate the safety and immunogenicity of 3D189 in patients with hematologic malignancies

To assess the safety, immunogenicity and preliminary efficacy of 3D189 in patients with hematological malignancies.

Phase 1 • Sponsor: 3D Medicines

Last updated Sep 10, 2026 15:00 UTC

A phase 2/3, multicenter, Double-Blind, randomized study to determine the efficacy and safety of tividenofusp alfa (DNL310) vs idursulfase in pediatric and young adult participants with neuronopathic or Non-Neuronopathic mucopolysaccharidosis type II

This is a Phase 2/3, multiregional, two-arm, double-blind, randomized, active (standard-of-care)-controlled study of the efficacy and safety of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme-replacement therapy (ERT) for mucopolysacch…

Phase 2/3 • Sponsor: Denali Therapeutics Inc.

Last updated Sep 10, 2026 15:00 UTC

Expanded-Coming-Out-Proud group on reducing self-stigma for people with a severe mental illness- a randomized control trial with six-month follow-up

Globally, approximately one-third of people with severe mental illness report self-stigma. Self-stigma negatively affects recovery by lowering quality of life, self-esteem, and self-efficacy, and reducing treatment adherence, which can lead individuals to refuse psychiatric medic…

Sponsor: City University of Hong Kong

Last updated Sep 10, 2026 15:00 UTC

Personalized ultrasonic brain stimulation for depression: a pilot study of target engagement and mood effects

This study will evaluate a new form of non-invasive brain stimulation for individuals with depression. Personalized low-intensity transcranial focused ultrasound stimulation will first be delivered using a range of stimulation parameters during psychological and physiological mon…

Phase 1/2 • Sponsor: University of Utah

Last updated Sep 10, 2026 15:00 UTC

Gonadotropin-releasing hormone agonist (GnRHa) plus letrozole in obese progestin-insensitive early-stage endometrial cancer patients with conservative treatment

To investigate the efficacy of GnRHa plus letrozole in obese progestin-insensitive EEC patients.

Phase 2/3 • Sponsor: Xiaojun Chen

Last updated Sep 10, 2026 15:00 UTC

Gonadotropin-releasing hormone agonist (GnRHa) plus letrozole in non-obese progestin-insensitive early-stage endometrial cancer and atypical hyperplasia patients with conservative treatment

To investigate the efficacy of GnRHa plus letrozole vs Diane-35 plus metformin in non-obese progestin-insensitive early-stage endometrial cancer (EEC) and atypical hyperplasia(EAH) patients asking for conservative treatment.

Phase 2/3 • Sponsor: Xiaojun Chen

Last updated Sep 10, 2026 15:00 UTC

Rapid acceleration of diagnostics underserved populations supplement rent relief and COVID-19 in st. louis: COVID-19 resource offers among rent and utility assistance applicants in st. louis

The purpose of this study is to evaluate health messaging strategies that help individuals with a high degree of housing-related needs engage in COVID-19 vaccination and testing behaviors. Findings from this research can help other communities determine how best to integrate soci…

Sponsor: Washington University School of Medicine

Last updated Sep 10, 2026 15:00 UTC

Clinical observation of the effect of ursodeoxycholic acid on parameters affecting liver, metabolic and cardiovascular morbidity and mortality - pilot project

Patients with NAFLD indicated for ursodeoxycholic acid treatment ("by SPC: cholestatic hepatitis") will be offered an observational study. Examinations will be performed before the treatment and after 6month period. Laboratory parameters, non-invasive indices, liver elastography,…

Sponsor: General University Hospital, Prague

Last updated Sep 10, 2026 15:00 UTC

A placebo-controlled, proof-of-concept study to evaluate the safety and efficacy of lanifibranor alone and in combination with the sodium-glucose transport protein 2 (SGLT2) inhibitor EmpaGliflozin in patiEnts with non-alcoholic steatohepatitis (NASH) and type 2 diabetes mellitus (T2DM)

The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.

Phase 2 • Sponsor: Inventiva Pharma

Last updated Sep 10, 2026 15:00 UTC

PRIME study: precision radiotherapy using MR-linac for pancreatic neuroendocrine tumours in MEN1 patients

Patients with the Multiple Endocrine Neoplasia type 1 (MEN1) syndrome are genetically predisposed for developping multiple pancreatic neuro-endocrine tumours (pNET). The management of small (pNET) in both MEN1 and sporadic cases, pose a major clinical challenge. At present, pancr…

Sponsor: J.M. de Laat

Last updated Sep 10, 2026 15:00 UTC

Randomized, delayed start, double blind, parallel group, placebo controlled, multicenter study of piromelatine 20 mg in participants with mild dementia due to Alzheimer's disease

Stopped early

Randomized efficacy and safety study of piromelatine 20 mg versus placebo in participants with mild dementia due to Alzheimer's disease (AD) who are 2:107,510,000-107,540,000 polymorphism non-carriers with the primary objective to compare the effect of piromelatine to that of pla…

Phase 2/3 • Sponsor: Neurim Pharmaceuticals Ltd.

Last updated Sep 10, 2026 15:00 UTC

Accelerometry and rehabilitation after knee replacement study (ARK): a prospective, randomised controlled trial.